Pfizer's PREVNAR 20™ Selected for Québec's Publicly Funded Pediatric Pneumococcal Immunization Program

KIRKLAND, QC, July 29, 2026 /CNW/ -- Pfizer Canada ULC is pleased to announce that its 20-valent pneumococcal conjugate vaccine, PREVNAR 20™ has been selected for the publicly funded pediatric pneumococcal immunization program in Québec.